本帖最后由 老马 于 2012-1-13 21:20 编辑 2 m) G0 ?1 w% T
8 p4 Y" B" r; g- T: \9 r% p爱必妥和阿瓦斯丁的比较( D0 o- W- m T! S* ]( q! y G
' n9 R7 n# M( \# K# c' dhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/
+ G3 v o1 d; I; z+ d5 T3 \5 Q
" r# G0 c( D* n# ?4 @
" g3 f6 j1 ?( q, l! h7 K/ @http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/% W. W5 r0 d3 V
==================================================2 Y' |7 T# G5 n5 a; t* z
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
2 i- W# L! M" Q) o7 BPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.3 v2 {* e; c* ~' T' Q" D$ e5 @8 l: u7 `
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported./ ~+ z. C- ]1 R, S8 ^& p
|